Jerusalem, however, announced that the effectiveness of the Pfizer-BioNTech vaccine was seen to be 64% against all COVID-19 infections — down from about 95% in May.
For Carl Zimmer's latest contributions to The Japan Times, see below:
The concerns about the shot mirror those about AstraZeneca’s, which European regulators began investigating last month after some recipients developed blood clots.
Experiments in test tubes suggest that some of its mutations allow the coronavirus to hold onto cells more tightly.
You might assume that 95 out of every 100 people vaccinated will be protected from COVID-19. But that’s not how the math works.
Coming a week after similar news from Pfizer and BioNTech, Moderna's announcement offered more hope that there’s going to be a way out of the pandemic.
The company's vaccine could require just one shot instead of two — important considering that the entire population of the world needs vaccination.